NEW YORK, NY / ACCESSWIRE / November 27, 2018 / The interview with Dwight Egan, CEO of Co-Diagnostics Inc, (CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is now available on www.wallstreetclub.com.
The interview addresses several questions regarding Co-Diagnostics’ recent and upcoming scientific, strategic, and commercial milestones, including the following excerpt discussing the potential for near-term revenue:
WSCtv: It sounds like you are building quite a lot of momentum in this regard as well. Where do you see that momentum leading?
Mr. Egan: Well of course, we see it leading to increased sales and profits. We are involved in three very strong verticals in addition to the opportunity to license our technology and our software to thousands of labs around the world who are doing research and development in very diverse areas of the genome, whether it’s animal, plant, or human. So, we are excited that during this fourth quarter we are going to be coming into revenues, and then continually growing that through 2019 and on to the future.
Video and full transcript of the interview can be found here:
About The Wall Street Club:
The Wall Street Club (WSC) is a financial digital media company whose focus is to provide readers with news and content on the latest trends and happenings in the financial industry. WSC accepts sole responsibility for the content and distribution of the foregoing release.
The Wall Street Club (WSC) does not hold any position in the company covered within the article. The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. The Wall Street Club is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
The Wall Street Club
SOURCE: Co-Diagnostics Inc